Raymond James analyst Jayson Bedford upgrades Stryker stock to outperform, predicting a price target of $418 within a year. Stryker has sustained 10%+ organic revenue growth for five years, but its stock underperformed due to a compressed P/E multiple. Bedford believes the current valuation is unjustified, but others disagree, suggesting the stock is overpriced at 46 times trailing earnings for just 10% growth. The Motley Fool Stock Advisor team does not include Stryker in its list of top 10 stocks, highlighting the potential for better returns elsewhere.

Read more at Yahoo Finance: Why Stryker Stock Popped Today